One challenge for Asia-Pacific countries is to ensure the provision of pharmaceuticals and other health technologies to their population in a sustainable manner. Beyond ensuring good quality and affordable supply, the question lies in how to encourage companies to produce innovation adapted to their medical needs and eventually to invest in developing additional services, production facilities and R&D on their territories. However, global and national companies, eager to optimise their investment policies across countries, are driven to consider favourable environment for arbitration.
The Third Health Policy Decision Makers Forum Asia-Pacific addressed:
Policy models considering their spill-overs and compatibility with sustainable and affordable access to care
Experiences and concerns from global companies investing in the Asia-Pacific region
Diversity of solutions for the region, considering the variety of economies and healthcare systems
The Health Forum is organized by:
The diversity of the Asia-Pacific region reflects different stages of development of the healthcare systems, from addressing essential needs to covering high technology solutions and encouraging industrial and research investments; however, it is a shared concern by government to extent or maintain universal coverage to meet growing needs whether due to ageing or the massive emergence of chronic diseases and hence provide access to affordable and good quality healthcare products;
Dialogue between governments and industry is highly advisable to minimize the gap between short term conflicting strategies in appearance (on the one hand, containing expenditure and lowering price, on the other hand maximizing profits in expanding markets) ; long term win-win relationships and attractiveness for investments are dependent upon the stability, predictability and sustainability of the political, economic and healthcare environment, which have dramatically improved in a number of countries in the region in the last decade;
Solutions to improve access to healthcare technologies and innovative medications are numerous, including information technologies utilisation, public-private partnerships, NGO’s collaborations and because of universal coverage extension and the rapid growth of the healthcare systems there are unique opportunities in the region, enforcing new models for the stakeholders, to the benefit of patients primarily and to the overall economic growth secondarily.
What they say
“This Forum is the third the ESSEC Institute of Health Economics and Management organized in Asia Pacific, with extended academic partnerships. It confirmed there is room for such an neutral and objective platform for exchange and discussion in the region and it gained both in geographical scope and depth, addressing a theme that so far had not been identified as one of the avenues toward improved access to care for patients.” - Annie Chicoye – Executive Director, Institute of Health Economics and Management "This Forum is dedicated to finding avenues of collaborations, partnerships and alternative solutions, with a specific difficulty in the region in that the region is quite heterogenous in terms of its development in both healthcare and economic growth." - Prof. Gerard de Pouvourville, Institute of Health Economics and Management
Institute of Health Economics and Management Sponsorship
The Institute benefits from educational grants from ABBVIE, DEERFIELD MANAGEMENT, IPSEN, JOHNSON&JOHNSON, MEDTRONIC, SANOFI, SHIRE, UCB and VIFOR PHARMA. It is fully dedicated to funding the development of activities of the Institute in Asia-Pacific, including the intensive HTA programmes and the Health Policy Forums.